Bristol-Myers Squibb Co vs Eaton Corporation plc — how do they compare? Bristol-Myers Squibb Co trades at $58.61 (market cap $116.30B), while Eaton Corporation plc trades at $412.45 (market cap $161.35B). The key difference: Eaton Corporation plc is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | ETN | |
|---|---|---|
Market Cap | $116.30B | $161.35B |
Sector | Health | Technology |
52-Week High | $62.37 | $435.78 |
52-Week Low | $42.60 | $315.82 |
Enterprise Value | $152.24B | $182.43B |
Dividend Yield | 4.42% | 1.06% |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Eaton Corporation (ETN) trades at $402.85, down 1.09% on the day, with a bearish technical signal from moving averages. The stock exhibits strong fundamentals, including a 13.99% net income margin and consistent quarterly earnings beats, most recently in Q1 2026. Recent news highlights growth in data center and aerospace markets, supported by strategic acquisitions and a $2.1 billion R&D investment in 2025.
The outlook remains positive, driven by robust analyst sentiment with a $449.50 consensus price target and no sell ratings. Key opportunities include exposure to high-growth infrastructure and AI-related power demand. Risks involve elevated valuation multiples, such as a P/E of 40.66, and potential execution challenges from recent investments, with Q2 2026 earnings on July 31, 2026, serving as a near-term catalyst.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →